Strong Industry Position Horizon Pharma, now part of Amgen, is strategically positioned within the biotechnology research industry with a notable presence in the drug and biopharmaceutical markets, offering significant opportunities to expand healthcare partnerships and distribution channels.

Recent Market Growth The launch of Pavblu biosimilar in 2024, with $700 million in sales and 21 percent quarter-over-quarter growth in 2025, indicates a robust product pipeline and strong customer demand, creating opportunities for upselling and cross-selling related biosimilar solutions.

Recognition & Credibility Amgen’s recognition as one of America's Best Large Employers and a top-ranked company in the Drugs & Biotechnology sector enhances its credibility and influence, making it easier to form strategic partnerships with healthcare providers, payers, and government agencies.

Engagement in Key Events Participation in major industry conferences such as the Virtual Oncology Leadership Summit and TD Cowen Healthcare Conference positions Amgen as an active industry leader, providing sales teams opportunities to connect with key decision-makers and stay abreast of emerging market trends.

Technology & Innovation Focus The company's adoption of advanced tech stacks including SuccessFactors, VMware Horizon, and Cortex XSOAR suggests a focus on digital transformation, which can enhance client engagement processes and streamline sales operations for new product rollouts and partnerships.